scholarly journals Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model

Gene Therapy ◽  
2014 ◽  
Vol 22 (1) ◽  
pp. 65-75 ◽  
Author(s):  
J J Ruotsalainen ◽  
M U Kaikkonen ◽  
M Niittykoski ◽  
M W Martikainen ◽  
C G Lemay ◽  
...  
Keyword(s):  
Colon Carcinoma ◽  
Interferon Response ◽  
Clonal Variation ◽  
Oncolytic Virotherapy ◽  
Ct26 Colon Carcinoma

Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma

2020 ◽  
Vol 13 (3) ◽  
pp. 245-250
Author(s):  
Mahdi Hatamipour ◽  
Mahmoud R. Jaafari ◽  
Amir A. Momtazi-Borojeni ◽  
Mahin Ramezani ◽  
Amirhossein Sahebkar
Keyword(s):  
Tumor Growth ◽  
Experimental Model ◽  
Colon Carcinoma ◽  
Carcinoma Cells ◽  
In Vivo Studies ◽  
Colon Carcinoma Cells ◽  
Ct26 Colon Carcinoma ◽  
Anti Tumor Activity

Background and Aims: Niclosamide is an established anti-helminthic drug, which has recently been shown to inhibit the growth of various cancer cells. To exploit the potential anti-tumor activity of this drug for systemic use, the problem of low aqueous solubility should be addressed. The present study tested the in vivo anti-tumor effects of a recently developed nanoliposomal preparation of niclosamide in an experimental model of colon carcinoma. Methods : The cytotoxicity of nanoliposomal niclosamide on CT26 colon carcinoma cells was evaluated using the MTT test. Inhibition of tumor growth was investigated in BALB/c mice bearing CT26 colon carcinoma cells. The animals were randomly divided into 4 groups including: 1) untreated control, 2) liposomal doxorubicin (15 mg/kg; single intravenous dose), 3) liposomal niclosamide (1 mg/kg/twice a week; intravenously for 4 weeks), and 4) free niclosamide (1 mg/kg/twice a week; intravenously for 4 weeks). To study therapeutic efficacy, tumor size and survival were monitored in 2-day intervals for 40 days. Results: In vitro results indicated that nanoliposomal and free niclosamide could exert cytotoxic effects with IC50 values of 4.5 and 2.5 μM, respectively. According to in vivo studies, nanoliposomal niclosamide showed a higher growth inhibitory activity against CT26 colon carcinoma cells compared with free niclosamide as revealed by delayed tumor growth and prolongation of survival. Conclusion : Nnaoliposomal encapsulation enhanced anti-tumor properties of niclosamide in an experimental model of colon carcinoma.

scholarly journals Novel hydro- and lipo-philic selenium zinc(II) phthalocyanines: Synthesis, photophysical properties and photodynamic effects on CT26 colon carcinoma cells

2018 ◽  
Vol 156 ◽  
pp. 133-139 ◽  
Author(s):  
Sergio D. Ezquerra Riega ◽  
Nicolás Chiarante ◽  
Federico Valli ◽  
Julieta Marino ◽  
Leonor P. Roguin ◽  
...  
Keyword(s):  
Colon Carcinoma ◽  
Photophysical Properties ◽  
Carcinoma Cells ◽  
Colon Carcinoma Cells ◽  
Ct26 Colon Carcinoma

Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells

2010 ◽  
Vol 199 (3) ◽  
pp. 277-287 ◽  
Author(s):  
Xu-Feng Qi ◽  
Dong-Heui Kim ◽  
Yang-Suk Yoon ◽  
Soo-Ki Kim ◽  
Dong-Qing Cai ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Colon Carcinoma ◽  
Carcinoma Cells ◽  
Colon Carcinoma Cells ◽  
Ct26 Colon Carcinoma ◽  
Induced Apoptosis

Soluble OX40L favors tumor rejection in CT26 colon carcinoma model

Cytokine ◽  
2016 ◽  
Vol 84 ◽  
pp. 10-16 ◽  
Author(s):  
Ekaterina O. Serebrovskaya ◽  
Diana V. Yuzhakova ◽  
Alina P. Ryumina ◽  
Irina N. Druzhkova ◽  
George V. Sharonov ◽  
...  
Keyword(s):  
Colon Carcinoma ◽  
Tumor Rejection ◽  
Ct26 Colon Carcinoma

scholarly journals Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Aditi Gupta ◽  
Sadna Budhu ◽  
Kelly Fitzgerald ◽  
Rachel Giese ◽  
Adam O. Michel ◽  
...  
Keyword(s):  
T Cell ◽  
Colon Carcinoma ◽  
Cell Function ◽  
Immune Checkpoint Blockade ◽  
Tumor Control ◽  
Myeloid Dendritic Cells ◽  
Functional Assays ◽  
Ct26 Colon Carcinoma ◽  
B16 Mouse Melanoma ◽  
Local Expression

AbstractTGFβ is a potential target in cancer treatment due to its dual role in tumorigenesis and homeostasis. However, the expression of TGFβ and its inhibition within the tumor microenvironment has mainly been investigated in stroma-heavy tumors. Using B16 mouse melanoma and CT26 colon carcinoma as models of stroma-poor tumors, we demonstrate that myeloid/dendritic cells are the main sources of TGFβ1 and TGFβ3. Depending on local expression of TGFβ isoforms, isoform specific inhibition of either TGFβ1 or TGFβ3 may be effective. The TGFβ signature of CT26 colon carcinoma is defined by TGFβ1 and TGFβ1 inhibition results in tumor delay; B16 melanoma has equal expression of both isoforms and inhibition of either TGFβ1 or TGFβ3 controls tumor growth. Using T cell functional assays, we show that the mechanism of tumor delay is through and dependent on enhanced CD8+ T cell function. To overcome the local immunosuppressive environment, we found that combining TGFβ inhibition with immune checkpoint blockade results in improved tumor control. Our data suggest that TGFβ inhibition in stroma poor tumors shifts the local immune environment to favor tumor suppression.

Sign in / Sign up

Export Citation Format

Share Document